Evidence map›Paper›PMID 27401888›Full record

ArticleThe oncologist2016

Chromosome 17p Homodisomy Is Associated With Better Outcome in 1p19q Non-Codeleted and IDH-Mutated Gliomas.

Marianne Labussière, Amithys Rahimian, Marine Giry, Blandine Boisselier, Yohann Schmitt, Marc Polivka, Karima Mokhtari, Jean-Yves Delattre, Ahmed Idbaih, Karim Labreche and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Marianne LabussièreSorbonne Universités, Université Pierre et Marie Curie, Université Paris 06, Centre de Recherche de l'Institut du Cerveau et de la Moelle Épinière, Paris, France INSERM U1127, Paris, France Centre National de la Recherche Scientifique, Unité de Recherche Mixte 7225, Paris, France.
Amithys RahimianSorbonne Universités, Université Pierre et Marie Curie, Université Paris 06, Centre de Recherche de l'Institut du Cerveau et de la Moelle Épinière, Paris, France INSERM U1127, Paris, France Centre National de la Recherche Scientifique, Unité de Recherche Mixte 7225, Paris, France OncoNeuroTek, Paris, France.
Marine GirySorbonne Universités, Université Pierre et Marie Curie, Université Paris 06, Centre de Recherche de l'Institut du Cerveau et de la Moelle Épinière, Paris, France INSERM U1127, Paris, France Centre National de la Recherche Scientifique, Unité de Recherche Mixte 7225, Paris, France.
Blandine BoisselierSorbonne Universités, Université Pierre et Marie Curie, Université Paris 06, Centre de Recherche de l'Institut du Cerveau et de la Moelle Épinière, Paris, France INSERM U1127, Paris, France Centre National de la Recherche Scientifique, Unité de Recherche Mixte 7225, Paris, France Plateforme de Génotypage Séquençage, Institut du Cerveau et de la Moelle Épinière, Paris, France.
Yohann SchmittSorbonne Universités, Université Pierre et Marie Curie, Université Paris 06, Centre de Recherche de l'Institut du Cerveau et de la Moelle Épinière, Paris, France INSERM U1127, Paris, France Centre National de la Recherche Scientifique, Unité de Recherche Mixte 7225, Paris, France.
Marc PolivkaLaboratoire d'Anatomie Pathologique, Hôpital Lariboisière, Assistance Publique Hôpitaux de Paris, Paris, France.
Karima MokhtariSorbonne Universités, Université Pierre et Marie Curie, Université Paris 06, Centre de Recherche de l'Institut du Cerveau et de la Moelle Épinière, Paris, France INSERM U1127, Paris, France Centre National de la Recherche Scientifique, Unité de Recherche Mixte 7225, Paris, France OncoNeuroTek, Paris, France Service de Neuropathologie Raymond Escourolle, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique Hôpitaux de Paris, Paris, France.
Jean-Yves DelattreSorbonne Universités, Université Pierre et Marie Curie, Université Paris 06, Centre de Recherche de l'Institut du Cerveau et de la Moelle Épinière, Paris, France INSERM U1127, Paris, France Centre National de la Recherche Scientifique, Unité de Recherche Mixte 7225, Paris, France OncoNeuroTek, Paris, France Service de Neurologie 2, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique Hôpitaux de Paris, Paris, France.
Ahmed IdbaihSorbonne Universités, Université Pierre et Marie Curie, Université Paris 06, Centre de Recherche de l'Institut du Cerveau et de la Moelle Épinière, Paris, France INSERM U1127, Paris, France Centre National de la Recherche Scientifique, Unité de Recherche Mixte 7225, Paris, France Service de Neurologie 2, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique Hôpitaux de Paris, Paris, France.
Karim LabrecheSorbonne Universités, Université Pierre et Marie Curie, Université Paris 06, Centre de Recherche de l'Institut du Cerveau et de la Moelle Épinière, Paris, France INSERM U1127, Paris, France Centre National de la Recherche Scientifique, Unité de Recherche Mixte 7225, Paris, France Division of Genetics and Epidemiology, The Institute of Cancer Research, Sutton, Surrey, United Kingdom marc.sanson@psl.aphp.fr.
Agusti AlentornSorbonne Universités, Université Pierre et Marie Curie, Université Paris 06, Centre de Recherche de l'Institut du Cerveau et de la Moelle Épinière, Paris, France INSERM U1127, Paris, France Centre National de la Recherche Scientifique, Unité de Recherche Mixte 7225, Paris, France Service de Neurologie 2, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique Hôpitaux de Paris, Paris, France.
Marc SansonSorbonne Universités, Université Pierre et Marie Curie, Université Paris 06, Centre de Recherche de l'Institut du Cerveau et de la Moelle Épinière, Paris, France INSERM U1127, Paris, France Centre National de la Recherche Scientifique, Unité de Recherche Mixte 7225, Paris, France OncoNeuroTek, Paris, France Service de Neurologie 2, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique Hôpitaux de Paris, Paris, France marc.sanson@psl.aphp.fr.
Inserm · FRInstitut du Cerveau · FRSorbonne Université · FRCentre National de la Recherche Scientifique · FRHôpital Lariboisière · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe 1p19q non-codeleted gliomas with IDH mutation, defined as "molecular astrocytomas," display frequent TP53 mutations and have an intermediate prognosis. We investigated the prognostic impact of copy number-neutral loss of heterozygosity (CNLOH) in 17p in this population.

methodsWe analyzed 793 gliomas (206 grade II, 377 grade III, and 210 grade IV) by single nucleotide polymorphism array and for TP53 mutations.

resultsHomodisomy revealed by CNLOH was observed in 156 cases (19.7%). It was more frequent in astrocytomas and oligoastrocytomas (98/256, 38%) than oligodendrogliomas (28/327, 8.6%; p < .0001) or glioblastoma multiforme (30/210, 14.3%; p < .0001), tightly associated with TP53 mutation (69/71 vs. 20/79; p = 2 × 10(-16)), and mutually exclusive with 1p19q codeletion (1/156 vs. 249/556; p < .0001). In the group of IDH-mutated 1p19q non-codeleted gliomas, CNLOH 17p was associated with longer survival (86.3 vs. 46.2 months; p = .004), particularly in grade III gliomas (overall survival >100 vs. 37.9 months; p = .007). These data were confirmed in an independent dataset from the Cancer Genome Atlas.

conclusionCNLOH 17p is a prognostic marker and further refines the molecular classification of gliomas. IMPLICATIONS FOR PRACTICE: Homodisomy of chromosome 17p (CNLOH 17p) is a frequent feature in IDH-mutated 1p19q non-codeleted gliomas (group 2). It is constantly associated with TP53 mutation. It was found, within this specific molecular group of gliomas (corresponding to molecular astrocytomas), that CNLOH 17p is associated with a much better outcome and may therefore represent an additional prognostic marker to refine the prognostic classification of gliomas.

Indexed as

AdultAgedBiomarkers, TumorChromosomes, Human, Pair 17Disease-Free SurvivalFemaleGliomaHumansIsocitrate DehydrogenaseLoss of HeterozygosityMaleMiddle AgedMutationPrognosisTumor Suppressor Protein p53Biomarkers, TumorIDH1 protein, humanIDH2 protein, humanIsocitrate DehydrogenaseTP53 protein, humanTumor Suppressor Protein p53Copy number neutral loss of heterozygosityGliomasTP53 mutation

Identifiers

PMID27401888
PMCPMC5016064
OpenAlexW2465512881

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.